Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression

Transplantation

Volumn 80, Issue 1, 2005, Pages 26-33

  Rogers, Christin C ^a   Alloway, Rita R ^b   Buell, Joseph F ^a   Boardman, Robyn ^a   Alexander, J Wesley ^a   Cardi, Michael ^c   Roy Chaudhury, Prabir ^b   First, M Roy ^d   Succop, Paul ^b   Munda, Rino ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHRIST HOSPITAL   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Corticosteroid withdrawal; Kidney transplant; Weight gain

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDOMINAL DISCOMFORT; AFRICAN AMERICAN; ANOREXIA; ARTICLE; BODY MASS; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; SIDE EFFECT; TASTE DISORDER; UREMIA; VOMITING; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; BODY MASS INDEX; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; SIROLIMUS; TIME FACTORS; WEIGHT GAIN;

EID: 22144442431     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000164290.17030.BC     Document Type: Article

References (12)

1. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 2000; 70 (11): SS41.
2. Kasiske BL. Cardiovascular disease after renal transplantation. Semin in Nephrol 2000; 20(2): 176.
3. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41(s5): S11.
4. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
5. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
6. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807.
7. Sharma AM. Obesity and cardiovascular risk. Growth Horm IGF Res 2003; 13(Suppl): S10.
8. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9(Suppl 4): 326S.
9. Gaber AO, Moore LW. Patters of early weight change after renal transplantation. J Ren Nutr 1996; 6: 21.
10. Baum CL, Thielke K, Westin E. Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition 2002; 18: 139.
11. van den Ham EC, Kooman JP, Christiaans MH, et al. Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transpl Int 2003; 16(5): 300.
12. van den Ham EC, Kooman JP, Christiaans MH, et al. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int 2003; 16(2): 82.